DeutschNewstral
Article
bizjournals.com on 2017-08-04 18:09
Ocular Therapeutix replaces regulatory chief after FDA rejection
Related news
- Bedford’s Ocular Therapeutix turns to layoffs after FDA rejectionbizjournals.com
- Shook Hardy adds former FDA associate chief counsel to regulatory practicebizjournals.com
FDA chief warns about kratom to treat opioid addiction; will seek more regulatory powerUSA today- MOcular Therapeutix shares rally after company submits FDA amendmentmarketwatch.com
- MOcular Therapeutix stock drops 10% after FDA warning lettermarketwatch.com
- Ocular Therapeutix faces fraud allegations as FDA rejects eye drugbizjournals.com
- Under SEC scrutiny, Bedford’s Ocular Therapeutix plans FDA do-overbizjournals.com
- MKala stock declines 6% after FDA approves ocular surgery productmarketwatch.com
- Cempra's stock down over FDA rejectionbizjournals.com
FDA Proposing Regulatory Shots in the Darkjdsupra.com- ICYMI: Biosimilars and FDA Regulatory Webinarjdsupra.com
- AI TRENDS FOR 2022 - FDA REGULATORYjdsupra.com
FDA chief stepping downPOLITICO- Cambridge's Akcea discloses layoffs after FDA drug rejectionbizjournals.com
- Austin drugmaker's stock falters after latest FDA rejectionbizjournals.com
- TransEnterix raised $26M leading up to FDA rejectionbizjournals.com
- FFDA arthritis drug rejection hits Eli Lilly sharesft.com
- Acer Therapeutics stock plummets 80 percent on FDA rejectionbizjournals.com
- Alkermes blames drug rejection on Covid halting FDA inspectionsbizjournals.com
- Drugmaker with new Waltham offices vows to fight FDA rejectionbizjournals.com